Research paper
Advances in Thalamic Neuromodulation for Epilepsy: From Mechanisms to Clinical Translation
Review of thalamic neuromodulation (DBS centromedian/anterior nucleus, RNS) for epilepsy. Covers indications, targeting strategies, outcomes, and emerging DEE applications.
Gonzalez-Martinez JA, et al.
Markdown path
content/research/papers/2026-gonzalez-martinez-thalamic-neuromodulation-epilepsy.mdFindings
Review of thalamic neuromodulation (DBS centromedian/anterior nucleus, RNS) for epilepsy. Covers indications, targeting strategies, outcomes, and emerging DEE applications.
Why it may matter for Levi
Thalamic DBS is a downstream neuromodulation option if Levi's DEE-SWAS becomes refractory to pharmacotherapy. Not near-term actionable but positions Levi's care pathway within the full treatment tier. Links to the Sanchez Fernandez 2012 and Van den Munckhof 2020 thalamic-injury literature already in the corpus.
Gonzalez-Martinez et al. (2026) — Thalamic neuromodulation perspective
Source
- Epilepsy Currents, 2026. AES Epilepsy Surgery Symposium perspective paper.
Why in corpus
Perspective paper arguing for a fundamental shift in thalamic neuromodulation strategy — from empiric one-size-fits-all targeting to patient-specific, hodology-informed approaches. Relevant to the DEE-SWAS population where thalamocortical dysfunction is central.
Key findings
- Effective thalamic neuromodulation requires patient-specific, hodology-informed target selection grounded in in situ electrophysiology and network-level biomarkers.
- Anterior nucleus of thalamus (ANT) is no longer universally optimal.
- Alternative targets — pulvinar, centromedian (CM), ventral motor thalamus — may be more appropriate depending on individual corticothalamic connectivity patterns.
- Emphasizes pre-surgical network mapping as a prerequisite for target selection.
Levi-relevant takeaways
- Thalamic DBS is investigational for non-lesional medically refractory DEE-SWAS (per Lapid & Varughese 2026). Not a near-term option for Levi given his favorable initial steroid response.
- If Levi were to become medically refractory and a neuromodulation trial became clinically indicated, the hodology-informed target-selection framework argues against default-ANT and in favor of individualized mapping — relevant for referral-site selection (few centers do this).
- Cleveland Clinic and a handful of other academic centers are implementing this framework; reasonable long-horizon reference if neuromodulation becomes relevant.